These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
268 related items for PubMed ID: 20628387
21. Deletion status of p16 in effusion smear preparation correlates with that of underlying malignant pleural mesothelioma tissue. Hida T, Matsumoto S, Hamasaki M, Kawahara K, Tsujimura T, Hiroshima K, Kamei T, Taguchi K, Iwasaki A, Oda Y, Honda H, Nabeshima K. Cancer Sci; 2015 Nov; 106(11):1635-41. PubMed ID: 26291840 [Abstract] [Full Text] [Related]
22. Up-regulation of DDX39 in human malignant pleural mesothelioma cell lines compared to normal pleural mesothelial cells. Kuramitsu Y, Tominaga W, Baron B, Tokuda K, Wang Y, Kitagawa T, Nakamura K. Anticancer Res; 2013 Jun; 33(6):2557-60. PubMed ID: 23749908 [Abstract] [Full Text] [Related]
23. Pleural effusion VEGF levels as a prognostic factor of malignant pleural mesothelioma. Hirayama N, Tabata C, Tabata R, Maeda R, Yasumitsu A, Yamada S, Kuribayashi K, Fukuoka K, Nakano T. Respir Med; 2011 Jan; 105(1):137-42. PubMed ID: 21041073 [Abstract] [Full Text] [Related]
24. TROP2 expression and SN38 antitumor activity in malignant pleural mesothelioma cells provide a rationale for antibody-drug conjugate therapy. Hegedüs L, Okumus Ö, Mairinger F, Ploenes T, Reuter S, Schuler M, Welt A, Vega-Rubin-de-Celis S, Theegarten D, Bankfalvi A, Aigner C, Hegedüs B. Lung Cancer; 2023 Apr; 178():237-246. PubMed ID: 36907051 [Abstract] [Full Text] [Related]
25. Mesothelin in serum and pleural effusion in the diagnosis of malignant pleural mesothelioma with non-positive cytology. Franceschini MC, Ferro P, Canessa PA, Battolla E, Dessanti P, Valentino A, Casolari L, Fontana V, Pezzi R, Fedeli F, Pistillo MP, Roncella S. Anticancer Res; 2014 Dec; 34(12):7425-9. PubMed ID: 25503183 [Abstract] [Full Text] [Related]
26. Cytokeratin 19 fragment/carcinoembryonic antigen ratio in pleural effusion is a useful marker for detecting malignant pleural mesothelioma. Suzuki H, Hirashima T, Kobayashi M, Sasada S, Okamoto N, Uehara N, Tamiya M, Matsuura Y, Morishita N, Kawase I. Anticancer Res; 2010 Oct; 30(10):4343-6. PubMed ID: 21036761 [Abstract] [Full Text] [Related]
27. Identification of DAB2 and Intelectin-1 as Novel Positive Immunohistochemical Markers of Epithelioid Mesothelioma by Transcriptome Microarray Analysis for Its Differentiation From Pulmonary Adenocarcinoma. Kuraoka M, Amatya VJ, Kushitani K, Mawas AS, Miyata Y, Okada M, Kishimoto T, Inai K, Nishisaka T, Sueda T, Takeshima Y. Am J Surg Pathol; 2017 Aug; 41(8):1045-1052. PubMed ID: 28394802 [Abstract] [Full Text] [Related]
28. Differential expression of extracellular matrix constituents and cell adhesion molecules between malignant pleural mesothelioma and mesothelial hyperplasia. Alì G, Borrelli N, Riccardo G, Proietti A, Pelliccioni S, Niccoli C, Boldrini L, Lucchi M, Mussi A, Fontanini G. J Thorac Oncol; 2013 Nov; 8(11):1389-95. PubMed ID: 24084442 [Abstract] [Full Text] [Related]
29. miR-130A as a diagnostic marker to differentiate malignant mesothelioma from lung adenocarcinoma in pleural effusion cytology. Cappellesso R, Galasso M, Nicolè L, Dabrilli P, Volinia S, Fassina A. Cancer Cytopathol; 2017 Aug; 125(8):635-643. PubMed ID: 28449331 [Abstract] [Full Text] [Related]
30. A proteomics-based approach identifies secreted protein acidic and rich in cysteine as a prognostic biomarker in malignant pleural mesothelioma. Kao SC, Kirschner MB, Cooper WA, Tran T, Burgers S, Wright C, Korse T, van den Broek D, Edelman J, Vallely M, McCaughan B, Pavlakis N, Clarke S, Molloy MP, van Zandwijk N, Reid G. Br J Cancer; 2016 Mar 01; 114(5):524-31. PubMed ID: 26889976 [Abstract] [Full Text] [Related]
31. Diagnostic value of mesothelin in pleural fluids: comparison with CYFRA 21-1 and CEA. Filiberti R, Parodi S, Libener R, Ivaldi GP, Canessa PA, Ugolini D, Bobbio B, Marroni P. Med Oncol; 2013 Jun 01; 30(2):543. PubMed ID: 23532816 [Abstract] [Full Text] [Related]
33. Re-directed T cells for the treatment of fibroblast activation protein (FAP)-positive malignant pleural mesothelioma (FAPME-1). Petrausch U, Schuberth PC, Hagedorn C, Soltermann A, Tomaszek S, Stahel R, Weder W, Renner C. BMC Cancer; 2012 Dec 22; 12():615. PubMed ID: 23259649 [Abstract] [Full Text] [Related]
34. Expression and role of GLUT-1, MCT-1, and MCT-4 in malignant pleural mesothelioma. Mogi A, Koga K, Aoki M, Hamasaki M, Uesugi N, Iwasaki A, Shirakusa T, Tamura K, Nabeshima K. Virchows Arch; 2013 Jan 22; 462(1):83-93. PubMed ID: 23187830 [Abstract] [Full Text] [Related]
35. Detection of TGF-β in pleural effusions for diagnosis and prognostic stratification of malignant pleural mesothelioma. Stockhammer P, Ploenes T, Theegarten D, Schuler M, Maier S, Aigner C, Hegedus B. Lung Cancer; 2020 Jan 22; 139():124-132. PubMed ID: 31778960 [Abstract] [Full Text] [Related]
38. Benign Pleural Mesothelial Cells Have Higher Osmotic Water Permeability than Malignant Pleural Mesothelioma Cells and Differentially Respond to Hyperosmolality. Katkova LE, Baturina GS, Bondar AA, Jagirdar RM, Hatzoglou C, Gourgoulianis KI, Solenov EI, Zarogiannis SG. Cell Physiol Biochem; 2019 Jan 22; 52(4):869-878. PubMed ID: 30958661 [Abstract] [Full Text] [Related]
39. Biomarkers for malignant pleural mesothelioma: a meta-analysis. Gillezeau CN, van Gerwen M, Ramos J, Liu B, Flores R, Taioli E. Carcinogenesis; 2019 Nov 25; 40(11):1320-1331. PubMed ID: 31169881 [Abstract] [Full Text] [Related]